Undervalued Drug Manufacturer Stocks on NAS May 2025

May 18, 2025

Drug Manufacturers

Drug Manufacturers are engaged in pharmaceutical manufacturing or sale of a diverse line of drug and healthcare products. This industry group also includes companies engaged in the development and discovery of new dugs, and tobacco and cannabis companies.

NASDAQ

The National Association of Securities Dealers Automated Quotations (Nasdaq) located in New York City, is the most active stock exchange by volume in the United States.

Our Valuation

A stock is considered undervalued if it trades at a discount to our valuation. To determine a stock’s intrinsic value, we developed an algorithm that uses 6 valuation models to determine the value of a company.* To learn more about stockcalc’s valuation methods, click here.

Undervalued Drug Manufacturers stocks

Stocks in this category are held primarily for potential income and capital appreciation.

For an in-depth look at the fundamentals and valuation of each company, try the stockcalc platform free for 30 days.

SymbolNameClose Price ($)Valuation ($)Difference (%)Average Vol (30D)Market Cap ($M)Yield (%)P/E Ratio
IRWD Ironwood Pharmaceuticals 0.57 1.45 154.17 2653136 92 0.00 0.0
AKAN Akanda 1.20 2.86 138.46 36450 1 0.00 0.0
TLRY Tilray Brands 0.49 1.17 135.77 23817875 450 0.00 0.0
SBFM Sunshine Biopharma 1.50 3.25 116.56 767191 1 0.00 0.0
ASRT Assertio Holdings 0.67 1.38 106.63 305643 64 0.00 0.0
RDHL Redhill Biopharma 1.85 3.70 100.17 301779 2 0.00 0.0
EVO Evotec 4.06 7.27 78.99 172029 1442 0.00 0.0
PCRX Pacira BioSciences 25.86 45.50 75.95 920868 1203 0.00 0.0
TXMD TherapeuticsMD 1.50 2.62 74.99 47528 17 0.00 0.0
EVOK Evoke Pharma 3.22 5.37 66.86 13254 6 0.00 0.0
All data provided as at market close May 15, 2025.

Company Details

Ironwood Pharmaceuticals

IRWD:NAS

Close Price

0.57

Our Valuation

1.45

% Difference

154.17

Market Cap ($M)

92

P/E Ratio

0.0

Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases.

Access the stockcalc valuation


Akanda

AKAN:NAS

Close Price

1.20

Our Valuation

2.86

% Difference

138.46

Market Cap ($M)

1

P/E Ratio

0.0

Akanda Corp is a cannabis cultivation, manufacturing, and distribution company. The company has three reportable segments: Cultivation, Distribution, and Corporate. A majority of its revenue is generated from the Distribution segment, which relates to the distribution of medical cannabis products, including cannabis oil and cannabis flower for medical use in the United Kingdom.

Access the stockcalc valuation


Tilray Brands

TLRY:NAS

Close Price

0.49

Our Valuation

1.17

% Difference

135.77

Market Cap ($M)

450

P/E Ratio

0.0

Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. US exposure consists of CBD products and alcohol.

Access the stockcalc valuation


Sunshine Biopharma

SBFM:NAS

Close Price

1.50

Our Valuation

3.25

% Difference

116.56

Market Cap ($M)

1

P/E Ratio

0.0

Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.

Access the stockcalc valuation


Access our valuation for these companies and 9,000+ more

Try the stockcalc platform free for 30 days

Sign Up

Assertio Holdings

ASRT:NAS

Close Price

0.67

Our Valuation

1.38

% Difference

106.63

Market Cap ($M)

64

P/E Ratio

0.0

Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.

Access the stockcalc valuation


Redhill Biopharma

RDHL:NAS

Close Price

1.85

Our Valuation

3.70

% Difference

100.17

Market Cap ($M)

2

P/E Ratio

0.0

Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin).

Access the stockcalc valuation


Evotec

EVO:NAS

Close Price

4.06

Our Valuation

7.27

% Difference

78.99

Market Cap ($M)

1442

P/E Ratio

0.0

Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health.

Access the stockcalc valuation


Pacira BioSciences

PCRX:NAS

Close Price

25.86

Our Valuation

45.50

% Difference

75.95

Market Cap ($M)

1203

P/E Ratio

0.0

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients.

Access the stockcalc valuation


TherapeuticsMD

TXMD:NAS

Close Price

1.50

Our Valuation

2.62

% Difference

74.99

Market Cap ($M)

17

P/E Ratio

0.0

TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories.

Access the stockcalc valuation


Evoke Pharma

EVOK:NAS

Close Price

3.22

Our Valuation

5.37

% Difference

66.86

Market Cap ($M)

6

P/E Ratio

0.0

Evoke Pharma Inc is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.

Access the stockcalc valuation


Access thousands of valuation reports

Try the stockcalc platform for 30 days for unlimited access to our valuation reports

Sign Up
Ironwood Pharmaceuticals and Akanda are the most undervalued Drug Manufacturers stocks on the NAS. See the full list on the blog: https://www.stockcalc.com/Blog/undervalued-drug-manufacturer-stocks-nas-may-2025
Ironwood Pharmaceuticals $IRWD and Akanda $AKAN are the most undervalued Drug Manufacturers stocks on the #NAS. See the full list: https://www.stockcalc.com/Blog/undervalued-drug-manufacturer-stocks-nas-may-2025
Ironwood Pharmaceuticals and Akanda are the most undervalued Drug Manufacturers stocks on the NAS. See the full list on the blog: https://www.stockcalc.com/Blog/undervalued-drug-manufacturer-stocks-nas-may-2025

Copyright © 2016- Patchell Brook Equity Analytics Inc. All rights reserved.

Risk Disclosure: Equities trading and trading of all markets, exchanges and instruments contains substantial risk and is not for every investor. An investor could potentially lose all or more than the initial investment. Risk capital is money that can be lost without jeopardizing ones’ financial security or life style. Only risk capital should be used for trading and only those with sufficient risk capital should consider trading. Past performance is not necessarily indicative of future results. View full risk information here.